Este archivo ha sido creado el 21.01.2025 por Matilde Durán Lobato GENERAL INFORMATION ------------------ 1. Dataset title: Dataset from Lipid nanoparticles as an emerging platform for cannabinoid delivery: physicochemical optimization and biocompatibility. Drug Development and Industrial Pharmacy, 42(2): 190-198. (v.0) 2. Authorship: [ Obligatorio | Ponga la información de todos los autores siguiendo el suiguiente formato. Repita el esquema para cada autor.] Matilde Durán-Lobato Universidad de Sevilla ORCID: 0000-0001-5534-6955 Email: mduran@us.es Lucía Martín-Banderas Universidad de Sevilla ORCID: 0000-0003-1447-6125 Email: luciamartin@us.es Rui Lopes Universidade de Lisboa ORCID: 0000-0002-6799-2740 Email: rlopes@ff.ulisboa.pt Lídia M. D. Gonçalves Universidade de Lisboa ORCID: 0000-0002-7807-4726 Email: lgoncalves@ff.ulisboa.pt Mercedes Fernández-Arévalo Universidad de Sevilla ORCID: 0000-0002-4283-3356 Email: mfarevalo@us.es António J. Almeida Universidade de Lisboa ORCID: 0000-0002-7807-4726 Email: aalmeida@ff.ulisboa.pt DESCRIPTION ---------- 1. Dataset language: English 2. Abstract: This dataset corresponds to the article "Lipid nanoparticles as an emerging platform for cannabinoid delivery: physicochemical optimization and biocompatibility," published in Drug Development and Industrial Pharmacy. The dataset includes experimental data on CB13-loaded lipid nanoparticles (LNPs) prepared using the emulsification-solvent evaporation method. Key data include particle size, polydispersity index (PDI), zeta potential, and stability studies in biorelevant fluids. Biocompatibility was assessed via cytotoxicity assays performed on NIH 3T3, HEK 293T, and Caco-2 cell lines. 3. Keywords: Lipid carriers; nanoparticle formulation; neuropathic pain; oral delivery; poorly soluble drugs Transportadores lipídicos, formulación de nanopartículas, dolor neuropático, liberación oral, fármacos de baja solubilidad 4. Date of data collection (fecha única o rango de fechas): 01.05.2013 – 31.12.2014 5. Publication Date: 21-05-2015 6. Grant information: [ Obligatorio si aplicable | Financiación recibida. Repita el esquema para cada organismo financiador.] Grant Agency: IV Plan Propio de la Universidad de Sevilla Grant Number: PhD grant of M. Durán-Lobato (USE-09090-M) Grant Agency: Junta de Andalucía Grant Number: Project P09-CTS-5029 Grant Agency: Fundação para a Ciência e a Tecnologia (FCT) Grant Number: PTDC/EBB-BIO/101237/2008 and PEst-OE/SAU/UI4013/2011, PhD grant of R. Lopes (SFRH/BD/44218/2008) 7. Geographical location/s of data collection: Facultad de Farmacia. Prof García González, 2, 41012 Sevilla, Andalucia, España Campus Reina Mercedes Coordinates: 37°21′39″N 5°59′18″O / 37.36094167, -5.98836111 ACCESS INFORMATION ------------------------ 1. Creative Commons License of the dataset: CC_BY 2. Dataset DOI: 3. Related publication: Durán-Lobato, M., Martín-Banderas, L., Lopes, R., Gonçalves, L.M.D., Fernández-Arévalo, M., Almeida, A.J. (2016). Lipid nanoparticles as an emerging platform for cannabinoid delivery: physicochemical optimization and biocompatibility. Drug Development and Industrial Pharmacy, 42(2): 190-198. DOI: 10.3109/03639045.2015.1038274. 4. Link to related datasets: VERSIONING AND PROVENANCE --------------- 1. Last modification date: 21-01-2025 2. Were data derived from another source?: NO 3. Additional related data not included in this dataset: METHODOLOGICAL INFORMATION ----------------------- 1. Description of the methods used to collect and generate the data: The dataset contains data from CB13-loaded LNPs prepared by emulsification-solvent evaporation. Particle characterization, including size, PDI, and zeta potential, was performed using dynamic light scattering (DLS). Drug encapsulation was measured using reverse-phase high-performance liquid chromatography (RP-HPLC). Stability studies evaluated particle behavior in simulated gastric and intestinal fluids. Cytotoxicity assays on NIH 3T3, HEK 293T, and Caco-2 cell lines were conducted using the MTT assay. Stability storage studies were performed at 4ºC. 2. Data processing methods: HPLC data were analyzed with Hitachi LaChrom® software. Statistical analyses, including ANOVA and Student’s t-tests, were conducted using SPSS, with p < 0.05 as the significance threshold. 3. Software or instruments needed to interpret the data: N/A 4. Information about instruments, calibration and standards: Nanoparticle Synthesis: Lipid nanoparticles (LNPs) were prepared using the emulsification-solvent evaporation method. A Branson Sonifier 250 (Branson Ultrasonics Corporation, USA) was used for sonication, followed by homogenization using a Silverson High-Speed Mixer L5 M (Silverson Machines, UK). Calibration was performed according to the manufacturer’s protocols. Physicochemical Characterization: Particle Size and Polydispersity Index (PDI): Measurements were conducted using a Malvern Zetasizer Nano ZS (Malvern Instruments Ltd., UK), calibrated with polystyrene standards to ensure accuracy. Samples were measured in triplicate at 25 ± 0.5°C. Zeta Potential: Also measured using the Malvern Zetasizer Nano ZS under identical calibration conditions, using the Smoluchowski model for electrophoretic mobility analysis. Drug Encapsulation Efficiency and Loading Capacity: Quantification of drug encapsulation and loading capacity was performed using reverse-phase high-performance liquid chromatography (RP-HPLC) on a Hitachi LaChrom® D-7000 system, equipped with a diode array UV-Vis detector and a Waters Spherisorb ODS2 column (4.6 × 250 mm, 5 µm). Calibration curves for CB13 were constructed using standards of known concentrations, ensuring linearity and reproducibility. Biocompatibility and Cytotoxicity: Cytotoxicity assays were performed on NIH 3T3, HEK 293T, and Caco-2 cell lines using the MTT assay, with absorbance read at 570 nm on a Tecan Infinite 200 Microplate Reader (Tecan Group Ltd., Switzerland). The reader was calibrated with standard absorbance filters before analysis. Stability Studies: Stability tests evaluated particle size and zeta potential over time in simulated gastric (pH 1.2) and intestinal fluids (pH 7.4) at 37°C, monitored using the Malvern Zetasizer Nano ZS. Calibration followed routine instrument guidelines for accuracy and precision. 5. Environmental or experimental conditions: N/A 6. Quality-assurance procedures performed on the data: [Opcional] FILE OVERVIEW ---------------------- [Se han de mencionar todos los archivos incluidos en el conjunto de datos, con el nombre y la extensión (.csv, .pdf, etc.) de cada archivo. Incluya la estructura de directorios]. 1. Explain the file naming conversion, si es aplicable: A single Excel file with each sheet collecting the data corresponding to a figure or table: -Figure 1: Data corresponding to manuscript Figure 1 on particle size zeta potential values of the formulations as a function on the different parameters assayed. -Figure 4: Data corresponding to manuscript Figure 4 on colloidal stability of the assayed formulations in biorelevant fluids. -Figure 5: Data corresponding to manuscript Figure 5 on the cytotoxic effect on NIH3T3 cells, HEK293T cells and Caco-2 cells of the different types of NPs assayed. -Figure A1: Data corresponding to manuscript Figure A1 on storage stability of the selected formulations. 2. File list: File name: Dataset from Lipid Nanoparticles as an Emerging Platform for Cannabinoid Delivery Description: A single Excel file with each sheet collecting the data corresponding to a figure or table: -Figure 1: Data corresponding to manuscript Figure 1 on particle size zeta potential values of the formulations as a function on the different parameters assayed. -Figure 4: Data corresponding to manuscript Figure 4 on colloidal stability of the assayed formulations in biorelevant fluids. -Figure 5: Data corresponding to manuscript Figure 5 on the cytotoxic effect on NIH3T3 cells, HEK293T cells and Caco-2 cells of the different types of NPs assayed. -Figure A1: Data corresponding to manuscript Figure A1 on storage stability of the selected formulations. 3. Relationship between files: [ Obligatorio si es aplicable | Relación entre los archivos] 4. File format: Excel 5. If the dataset includes multiple files, specify the directory structure and relationships between the files: [ Obligatorio si es aplicable | Si el conjunto de datos incluye varios archivos, indique la estructura de directorios y las relaciones entre los archivos] SPECIFIC INFORMATION FOR TABULAR DATA ------------------------------------------- [Este apartado se debe repetir para cada archivo de datos que requiera la explicación de variables (habitualmente datos tabulados). Se describirán todas las variables, incluyendo las unidades de medida.] 1. Name file: [Opcional | Nombre del archivo] 2. Number of rows and columns: [Opcional |Número de filas y columnas] 3. Variables list: [Opcional | Repita la estructura para cada variable.] Variable name: Description: Units of measure or value labels | Unidades de medida o etiquetas de valor: 4. Codes or symbols for missing data: [Opcional | Repita la estructura para cada código o símbolo que faltan] Code or symbol: Definition: 5. Special formats or abbreviations used: [Opcional |Formatos especiales o abreviaturas utilizadas] MORE INFORMATION -------------- [Include any other information about the dataset that is not reflected in this template and that you consider relevant. Incluya cualquier otra información sobre el conjunto de datos que no haya quedado reflejada en esta plantilla y que considere relevante]